Press "Enter" to skip to content

New patent for Boehringer Ingelheim drug SYNJARDY XR

0
Copyright © DrugPatentWatch. Originally published at New patent for Boehringer Ingelheim drug SYNJARDY XR

Annual Drug Patent Expirations for SYNJARDY+XR
Annual Drug Patent Expirations for SYNJARDY+XR

Synjardy Xr is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are four patents protecting this drug and one Paragraph IV challenge.

SYNJARDY XR drug price trends.

Drug patent litigation for SYNJARDY XR.

This drug has one hundred and forty-two patent family members in thirty-eight countries.

The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. One supplier is listed for this compound. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Copyright © DrugPatentWatch. Originally published at New patent for Boehringer Ingelheim drug SYNJARDY XR
    Do NOT follow this link or you will be banned from the site!